Gene therapy for wet age-related macular degeneration
Part of Eyes & vision clinical trials.
This trial tests a gene therapy called LX109 for wet age-related macular degeneration (AMD), a condition where abnormal blood vessels damage the retina. The therapy aims to reduce the need for frequent eye injections by providing a longer-lasting treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 50 years old or older.
- You must have wet age-related macular degeneration (AMD) with active signs of abnormal blood vessel growth in the eye.
- Your vision in the study eye must be within a certain range (roughly 20/400 to 20/40).
- You must have had at least 2 anti-VEGF injections (like Eylea or Lucentis) in the past 6 months.
- You should not have other serious eye conditions (like diabetic retinopathy or retinal detachment) in the study eye.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy (LX111) for people with wet age-related macular degeneration (AMD) who have already been helped by standard anti-VEGF injections. The goal is to see if one dose of LX111 can reduce the need for frequent eye injections.
This study tests a one-time gene therapy called LX102 for wet age-related macular degeneration (AMD). It may reduce the need for frequent eye injections and help preserve vision.
This trial tests a gene therapy (KH658) as a one-time treatment for wet macular degeneration. It's for people whose condition has been stabilized with anti-VEGF injections, and aims to see if it is safe and can reduce the need for frequent eye injections.
This trial tests a one-time gene therapy injection (IXO-vec) for people with wet age-related macular degeneration (nAMD). It aims to reduce the need for frequent eye injections by helping the eye make its own medicine to block the growth of harmful blood vessels.
This trial tests a new gene therapy called RRG001 for people with the 'wet' form of age-related macular degeneration. It aims to treat leaky blood vessels in the eye that can cause vision loss, possibly reducing the need for frequent eye injections.
This trial tests a one-time gene therapy injection under the retina for people with wet age-related macular degeneration (AMD), which causes blurry vision from abnormal blood vessels. It aims to reduce the need for frequent eye injections by delivering a treatment that may help the eye produce its own medicine.
Hear when a new To Evaluate the Safety and Tolerability of Intravitreal Injection of LX109 in Patients With nAMD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.